Novartis sees EU, Swiss drop antitrust probes into 'blocking patent'

By Lewis Crofts ( October 10, 2024, 06:39 GMT | Insight) -- Novartis's move to acquire patents for a psoriasis drug from Genentech and then enforce them against rival drugmaker Eli Lilly have escaped antitrust prosecution after regulators in the EU and Switzerland ended their probes without finding any illegal conduct. The Swiss competition authority said Novartis' behavior had been in line with normal conduct under patent law. The European Commission confirmed closure of its own probe, saying there weren't "sufficient grounds" to continue looking into the company.Novartis's move to acquire patents for a psoriasis drug from Genentech and then enforce them against rival drugmaker Eli Lilly have escaped antitrust prosecution after regulators in the EU and Switzerland ended their probes without finding any illegal conduct....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Novartis sees EU, Swiss drop antitrust probes into 'blocking patent'

Prepare for tomorrow’s regulatory change, today

Related Sections